From The Editor
-
Single-Use Standardization Starts At Home
8/28/2025
During a Bioprocess Online Live event, “Single-Use Harmonization Needs A Tune Up," panelists discuss a way forward for the industry to unlock the true flexibility and promise of single-use technology.
-
Biopharma Manufacturing Outsourcing Is Flexible, Not Fractured
8/21/2025
An element of the 2025 BioPlan Associates annual report and survey took Chief Editor Louis Garguilo by surprise. The report intimates that biopharmaceutical manufacturing faces a fractured CDMO market. Despite solid data to back that assertion up, Garguilo presents a very different view, one based on what many readers have expressed.
-
Unlocking The Pharmacological Potential Of Antibodies
8/20/2025
Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains the company's Functional Antibody Selection Technology (FAST) platform and its approach to developing a pipeline of G protein-coupled receptor (GPCR) mAbs.
-
Tech Transfer 2025 – A High-Stakes Game Of Trust
8/4/2025
Trust us. You'll want to read this editorial from Chief Editor Louis Garguilo, who was (gently) reminded he hadn't visited the subject of tech transfer in a while. He answers the questions both sponsors and CDMOs ask to gain the trust to make a tech transfer work for both sides.
-
How Lumen Is Putting The "Farm" In Biopharma
7/31/2025
Lumen Bioscience's SVP of production and development, Craig Behnke, Ph.D., explains how the company is cutting costs and rethinking upstream manufacturing with its algae-based production platform.
-
The Safety Potential Of Conditionally Active Biologics
7/28/2025
Conditionally active biologics (CABs) are an emerging class of therapies that can reduce off-target toxicity in the clinic, and they were a topic of conversation at the 2025 BIO International Convention.
-
CDMOs Should Stop Stringing Biotechs Along
7/28/2025
Biotechs, first working closely with a CDMO’s sales manager, experience subsequent and sudden rejections of their projects. Did some of you just wince? If so, that might be because we are again hearing of a problem with sudden rejections after protracted discussions and even site visits. Part two on what is one of the biggest problems for outsourcing today.
-
FDA Leading The Decline Of Animal Testing
7/16/2025
The gold standard practice of conducting animal studies for evaluating toxicity, pharmacodynamics, and immunogenicity is being challenged by innovative alternatives – New Approach Methods (NAMs).
-
Governor Josh Shapiro On Supporting Biomanufacturing In Pennsylvania
7/15/2025
Bioprocess Online's coverage of Governor Josh Shapiro’s fireside chat with BIO CEO, John Crowley, at the 2025 BIO International Convention.
-
How CGT Leaders Are Reducing Failures, Scaling Processes, And Overcoming Regulatory Friction
6/30/2025
Industry leaders share their philosophy on reducing product failure, embracing AI, and building dynamic teams to stay ahead of the curve to bring curative CGT therapies to patients.